5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Peroxisome proliferator-activated receptor gamma (PPARG) gene amplifications in urothelial carcinoma (UC)
    Meeting Abstract

    Bambury, R. M.; Iyer, G.; Riester, M.; Werner, L.; Schultz, N.; Stack, E. C.; Park, R.; Loda, M.; Ostrovnaya, I.; Kantoff, P. W.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Association of IL8 polymorphisms with overall survival in patients with renal cell carcinoma in COMPARZ (pazopanib versus sunitinib phase III study)
    Meeting Abstract

    Xu, C. F.; Johnson, T.; Choueiri, T. K.; Deen, K. C.; Xue, Z.; Spraggs, C. F.; Bartlett-Pandite, A. N.; Carpenter, C.; Motzer, R. J.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Genomic heterogeneity of circulating tumor cells in castration-resistant prostate cancer (CRPC) revealed by single-cell sequencing
    Meeting Abstract

    Welsh, A.; Danila, D. C.; Anand, A.; Kendall, J.; Sawyers, C. L.; Fleisher, M.; Wigler, M.; Hicks, J. B.; Scher, H. I.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Effective monotherapy despite intratumor heterogeneity: Clonal convergence within the PI3K pathway and sensitivity to mTOR inhibitors in patients with advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Voss, M. H.; Hakimi, A. A.; Chen, Y.; Pham, C. G.; Brannon, A. R.; Scott, S. N.; Takeda, S.; Liu, H.; Motzer, R. J.; Berger, M. F.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Tivozanib in patients treatment-naive for metastatic renal cell carcinoma: A subset analysis of the phase III TIVO-1 study
    Meeting Abstract

    Sternberg, C. N.; Eisen, T.; Tomczak, P.; Strahs, A. L.; Esteves, B.; Berkenblit, A.; Motzer, R. J.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Sera cytokine levels to predict survival in men with progressive castration-resistant prostate cancer
    Meeting Abstract

    Subudhi, S. K.; Heller, G.; Danila, D. C.; Anand, A.; Lacuna, K. P.; Samoila, A.; Fleisher, M.; Scher, H. I.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Chimeric antigen receptor (CAR(+)) modified T cells targeting prostate specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC)
    Meeting Abstract

    Slovin, S. F.; Wang, X.; Hullings, M.; Arauz, G.; Bartido, S.; Lewis, J. S.; Schoder, H.; Zanzonico, P.; Scher, H. I.; Riviere, I.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A pilot study comparing circulation tumor cells (CTC) detection by AdnaTest prostate assay to CellSearch in patients (pts) with castration resistant prostate cancer (CRPC)
    Meeting Abstract

    Samoila, A.; Bastos, D. A.; Herkal, A.; Patel, C.; Curtis, K. R.; Schreiber, N. A.; Anand, A.; Fleisher, M.; Scher, H. I.; Danila, D. C.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • An exploratory analysis of bone scan lesion area (BSLA), circulating tumor cell (CTC) change, pain reduction, and overall survival (OS) in patients (pts) with castration-resistant prostate cancer (CRPC) treated with cabozantinib (cabo): Updated results of a phase II nonrandomized expansion (NRE) cohort
    Meeting Abstract

    Scher, H. I.; Smith, M. R.; Sweeney, C.; Corn, P. G.; Logothetis, C.; Vogelzang, N. J.; Smith, D. C.; Hussain, M.; George, D. J.; De Bono, J. S.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • The Borealis-2 clinical trial: A randomized phase II study of OGX-427 plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer
    Meeting Abstract

    Rosenberg, J. E.; Hahn, N. M.; Regan, M. A.; Jacobs, C.; Stewart, P. S.; Choueiri, T. K.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save